Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1186868 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1189648 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1188688 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1187574 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1188509 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1188914 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1187612 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1188814 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1188915 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 | |
| SCHEMBL1187998 | 1.00 | KCNH2 (0.47) | KCNH2NOS2PTGS2GPR84ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2008319-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116001-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | TPR, ROR1, CA3 | KCNH2 3391/4885NOS2 2789/4885PTGS2 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.